Main menu

Recent Pfizer Press Releases

10/29/14 2:44pm EDT
Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults

TRUMENBA is the First and Only Approved Vaccine in the U.S. for the Prevention of Meningococcal Meningitis B

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.

more...
10/29/14 8:30am EDT
Pfizer’s PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder

Study Also Reinforces Existing Body of Clinical Evidence in Support of the Efficacy, Safety and Tolerability Profiles of PRISTIQ

Pfizer Inc.

more...
10/28/14 7:00am EDT
PFIZER REPORTS THIRD-QUARTER 2014 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2014.

more...
10/23/14 4:05pm EDT
Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend

Board of Directors Authorizes New $11 Billion Share Repurchase Program

10/23/14 8:00am EDT
Pfizer Wins SUTENT® Patent Case In Delaware District Court

Pfizer Inc. announced today that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering SUTENT® (sunitinib malate) capsules. This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as SUTENT to patients through the term of the patent, which expires in 2021.

 

more...
10/17/14 4:38pm EDT
FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII

EMBEDA is the first and only approved ER morphine specifically designed to deter oral and intranasal abuse when crushed

Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has approved an updated label for EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, for oral use, CII, to include abuse-deterrence studies. The updated label states that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal (i.e., snorting) routes when crushed. However, abuse of EMBEDA by these routes is still possible.

more...
10/13/14 8:00am EDT
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review

NDA Requests Approval of Palbociclib as a First-Line Therapy in Combination with Letrozole for ER+, HER2- Advanced Breast Cancer
 

Pfizer Inc. today announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA).

more...
10/10/14 8:00am EDT
Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™

Rapid and sustained response in functional antibody titers observed following single-dose administration of a novel, investigational 4-antigen Staphylococcus aureus vaccine (SA4Ag) to healthy adults

Pfizer announced today that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus (S. aureus) candidate vaccine (SA4Ag) in healthy adults.

more...
10/8/14 8:30am EDT
Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer

  • Metastatic breast cancer currently affects 150,000-250,000 people in the U.S. and remains an incurable condition1,2
  • New initiative aims to expand the breast cancer conversation to be more inclusive of metastatic disease

This October, Pfizer Inc. is uniting with leaders in the breast cancer community in a public call-to-action to expand the breast cancer dialogue to include metastatic breast cancer. This comes after a first-of-its-kind survey commissioned by Pfizer revealed that many people know little to nothing about metastatic breast cancer – the most advanced stage of breast cancer (Stage IV), in which cancer has spread beyond the breast to other organs in the body.2,3

more...
10/8/14 8:00am EDT
Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine

Data From This Study Will Be Presented At IDWeek 2014™ In Philadelphia

Pfizer Inc. (NYSE:PFE) announced today it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086 (rLP2086), with a licensed quadrivalent human papillomavirus vaccine (HPV4), at IDWeek 2014™ in Philadelphia. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4.

more...
9/29/14 8:00pm EDT
Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study

Agreement to Combine Kyowa Hakko Kirin’s Anti-CCR4 Antibody Mogamulizumab and Pfizer’s investigational 4-1BB agonist (PF-05082566) in Clinical Study

Pfizer Inc.

more...
9/25/14 8:00am EDT
Pfizer Completes Acquisition Of InnoPharma

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States (U.S.) regulatory approval from all government authorities required by the agreement and other closing conditions.
 
 

more...
9/23/14 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 28, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2014 Performance Report, to be issued that morning.

 

more...
9/23/14 8:00am EDT
Kim Cattrall Encourages Women to Embrace Menopause with Style

Pfizer launches new campaign to inspire postmenopausal women to tune into their bodies

Every day, an estimated 6,000 women in the United States reach menopause.1 To inspire this growing pop

more...
9/19/14 8:00am EDT
Pfizer Foundation Provides $2 Million In Grants To Support ‘Last-Mile’ Vaccine Coverage In Africa

  • Efforts in support of the United Nations Millennium Development Goal (MDG) 4 to reduce under-5 child mortality rate.
  • Programs designed to reach children in remote locations in five African countries.

The Pfizer Foundation today announced $2 million in grant funding for pilot programs to improve immunization coverage in Africa. The programs will focus on ‘last-mile’ interventions to reach underserved populations living in Ethiopia, Malawi, Rwanda, Uganda and Zambia.

more...
9/3/14 10:00am EDT
Pfizer Invites the Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2014 at 12:55 p.m. Eastern Daylight Time.

more...
8/28/14 1:15pm EDT
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease

 
Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection for pediatric patients. ELELYSO is therefore now indicated for long-term enzyme replacement therapy (ERT) for adult and pediatric patients with a confirmed diagnosis of Type 1 Gaucher disease.
 

more...

Pages